Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia

Journal of Clinical Lipidology

Volumn 5, Issue 4, 2011, Pages 299-307

  Harris, Leonard J ^a,b   Thapa, Rashmi ^a   Brown, Michael ^a   Pabbathi, Sabitha ^a   Childress, Richard D ^a   Heimberg, Murray ^a   Braden, Ron ^a   Elam, Marshall B ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Lipid; Myalgia; Myopathy; Statin

Indexed keywords

ATORVASTATIN; BILE ACID SEQUESTRANT; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; LIPOPROTEIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG HYPERSENSITIVITY; DRUG INTERACTION; ELECTROLYTE DISTURBANCE; FEMALE; FOLLOW UP; HOSPITAL; HUMAN; HYPERTENSION; KIDNEY DISEASE; LABORATORY TEST; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; THYROID DISEASE;

AGED; CASE-CONTROL STUDIES; CREATINE KINASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MUSCULAR DISEASES; MYOSITIS; PAIN; PHENOTYPE;

EID: 79960769589     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2011.05.005     Document Type: Article

References (32)

1. J.C. LaRosa, J. He, and S. Vupputuri Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346 (Pubitemid 30013066)
2. P.M. Ridker, J.G. MacFadyen, and F.A. Fonseca Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes 2 2009 616 623
3. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines Circulation 110 2004 227 239 (Pubitemid 38924592)
4. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Circulation 106 2002 1024 1028 (Pubitemid 34925341)
5. C.M. Ballantyne, A. Corsini, and M.H. Davidson Risk for myopathy with statin therapy in high-risk patients Arch Intern Med 163 2003 553 564 (Pubitemid 36314342)
6. E. Bruckert, G. Hayem, S. Dejager, C. Yau, and B. Begaud Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study Cardiovasc Drugs Ther 19 2005 403 414 (Pubitemid 43228152)
7. H. Bays Statin safety: an overview and assessment of the data - 2005 Am J Cardiol 97 8A 2006 6C 26C
8. R.C. Pasternak, S.C. Smith Jr., C.N. Bairey-Merz, S.M. Grundy, J.I. Cleeman, and C. Lenfant ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins Stroke 33 2002 2337 2341 (Pubitemid 35014654)
9. R.R. Sokal, and F.J. Rohlf Biometry: The Principles and Practice of Statistics in Biological Research 3rd ed. 1995 W.H. Freeman New York
10. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
11. T.R. Joy, and R.A. Hegele Narrative review: statin-related myopathy Ann Intern Med 16 150 2009 858 868
12. E. Link, S. Parish, and J. Armitage SLCO1B1 variants and statin-induced myopathy - a genomewide study N Engl J Med 359 2008 789 799
13. D. Voora, S.H. Shah, and I. Spasojevic The SLCO1B15 genetic variant is associated with statin-induced side effects J Am Coll Cardiol 54 2009 1609 1616
14. E.A. Stein, C.M. Ballantyne, and E. Windler Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins Am J Cardiol 101 2008 490 496 (Pubitemid 351199443)
15. C.J. Glueck, D. Aregawi, M. Agloria, Q. Khalil, M. Winiarska, J. Munjal, S. Gogineni, and P. Wang Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies Clin Ther 28 2006 933 942 (Pubitemid 44062693)
16. R. Laaksonen, M. Katajamaa, and H. Paiva A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle PLoS ONE 1 2006 e97
17. N.S. Palikhe, S.H. Kim, and H.S. Park What do we know about the genetics of aspirin intolerance? J Clin Pharm Ther 33 2008 465 472
18. J. Sacher, L. Weigl, M. Werner, C. Szegedi, and M. Hohenegger Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells J Pharmacol Exp Ther 314 2005 1032 1041 (Pubitemid 41205966)
19. H. Sinzinger, F. Chehne, and G. Lupattelli Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy Drug Saf 25 2002 877 883 (Pubitemid 35178645)
20. H. Charles, C.B. Good, B.H. Hanusa, C.C. Chang, and J. Whittle Racial differences in adherence to cardiac medications J Natl Med Assoc 95 2003 17 27 (Pubitemid 37101972)
21. P.F. Ama, J.A. Simoneau, M.R. Boulay, O. Serresse, G. Theriault, and C. Bouchard Skeletal muscle characteristics in sedentary black and Caucasian males J Appl Physiol 61 1986 1758 1761 (Pubitemid 17196231)
22. P.J. Neuvonen Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics Curr Opin Investig Drugs 11 2010 323 332
23. S.K. Baker Molecular clues into the pathogenesis of statin-mediated muscle toxicity Muscle Nerve 31 2005 572 580 (Pubitemid 40577779)
24. B.A. Golomb, and M.A. Evans Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism Am J Cardiovasc Drugs 8 2008 373 418
25. P.S. Phillips, R.H. Haas, and S. Bannykh Statin-associated myopathy with normal creatine kinase levels Ann Intern Med 137 2002 581 585
26. P. Sirvent, J. Mercier, and A. Lacampagne New insights into mechanisms of statin-associated myotoxicity Curr Opin Pharmacol 8 2008 333 338
27. W. Ahmed, N. Khan, and C.J. Glueck Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients Translational Res 153 2009 11 16
28. B. Noel Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review J Eur Acad Dermatol Venereol 21 2007 17 24 (Pubitemid 44942318)
29. G. Ruano, P.D. Thompson, and A. Windemuth Physiogenomic association of statin-related myalgia to serotonin receptors Muscle Nerve 36 2007 329 335 (Pubitemid 47326011)
30. G.D. Vladutiu Genetic predisposition to statin myopathy Curr Opin Rheumatol 20 2008 648 655
31. J. Oh, M.R. Ban, B.A. Miskie, R.L. Pollex, and R.A. Hegele Genetic determinants of statin intolerance Lipids Health Dis 6 2007 7
32. M. Niemi Transporter pharmacogenetics and statin toxicity Clin Pharmacol Ther 87 2010 130 133